Paris, March 24, 2011

STENTYS REPORTS FY 2010 FINANCIAL RESULTS

- **Operational expenses aligned with plan**
- **Solid cash position to continue myocardial infarction market development**

STENTYS (FR0010949404 – STNT), a medical technology company that markets a new generation of innovative stents for the treatment of acute myocardial infarction (AMI), reported today its audited annual financial statements for the fiscal year 2010, ending December 31, 2010, and approved by the company Board of Directors on March 23 2011.

- **Annual Results for 2010***

En K€	**December 31, 2010**	December 31, 2009
Revenues	**305.6**	0
**Operating expenses ** **	**(8,141.0)**	(4,572.6)
*Of which, share-based payments****	*(504.7)*	*(550.8)*
Operating results prior to share-based payments (loss)	**(7,636.3)**	(4,021.8)
Operating results after share-based payments (loss)	(7,835.4)	(4,572.6)
Net Result (loss)	**(7,767.6)**	(4,584.6)

The company began to market its products during the year 2010. Therefore, there was no turnover during the year 2009.
* *Audited amounts, IFRS Standards*
** *COGS included*
*** *Non-cash item*

Rapid increase in activity

As previously announced, STENTYS recognized an annual turnover of 305.6 thousand Euros during the year 2010. Since receiving CE Mark for its products early 2010, the company's activity has continuously increased following the market launch of the STENTYS stent, first in The Netherlands and later in Germany. From the first to the second semester, the company's activity increased by +223,3% and reached 233.4 thousand Euros in the last six months of financial year 2010.

Operating Expenses: an increase to position STENTYS for growth

Compared to the 4.6 Million Euros incurred for the year 2009, operating expenses during the year 2010 were of 8.1 Million Euros, as anticipated. This increase reflects the way STENTYS has positioned itself for growth, along with the logical re-allocation of its operating expenses. If the Research and Development, Sales and Marketing, and General and Administrative expenses accounted for 59%, 30%, and 11% of the 2009 operating expenses respectively (not including shared-based payments), the 2010 breakdown evolved as follows: 29% in Research and Development, 51% in Sales and Marketing, 18% in General and Administrative, the remaining 2% representing the costs of goods sold.

When going into details, changes in each of these accounts are related to the following investments:

- Research and Development: 2.2 Million Euros

Having obtained the CE Mark for its products in 2010, the Company continues to invest in its Research activities to prepare for the IDE (Investigational Device Exemption) and refine its current products. Nevertheless, the 2.2 Million Euros spent on Research and Development in the year 2010 are 8% lower than the 2.4 Million Euros spent on this same department in 2009.

- Sales and Marketing: 3.9 Million Euros

The department's spending accounted for 1.2 Million Euros in 2009, an amount which has increased considerably for the market launch of its products, as expected by the Company.

This increase in expenses is justified by:

  - The recruitments for the European sales force in view of the market launch of its stents in an increasing number of countries;
  - The APPOSITION II randomized study, that enrolled 80 patients in 10 centres in Europe and demonstrated the perfect apposition of the STENTYS stents compared to the high rate of malapposition of competitive stents ;
  - The launch of the APPOSITION III international clinical study and the recruitment of 50 patients by the end of December 2010, out of the 500 required for the full study.

- General and Administrative: 1.3 Million Euros

The increase in overhead costs reflects the way the Company has positioned itself for growth, namely with the recruitment of a production director and a Chief Financial Officer, the expansion of their headquarters, and the expenses related to the listing on a public stock exchange.

- **Cash**

STENTYS' cash as of December 31 2010 was 22.2 Million Euros, an amount vouching for the soundness of the company's financial structure, thanks to the 22.7 Million Euros capital increase obtained with the Company's Initial Public Offering. STENTYS' operating cash outflows reached 6.8 Million Euros for the financial year.

- **2010 Milestones and Recent Events**

- Sales and Marketing

CE Mark approval of the "BMS" (Bare Metal Stent) and "DES" (Drug Eluting Stent) self-apposing stents and market launch of BMS stents in Germany and the Netherlands in the first semester of 2010

In addition, the Company expanded operations in four additional European countries in 2011: Scandinavia, Spain, Switzerland, and Poland.
In February 2011 STENTYS also announced an increase in reimbursement for its drug eluting stent (DES) in Germany, a decision which should reinforce STENTYS' activities in the region.

Presentation of the Apposition II clinical trial results

On September 22, 2010, STENTYS announced the results of the Apposition II international clinical trial that enrolled 80 patients in six countries. The study indisputably demonstrated that the STENTYS stent eliminates malapposition compared with conventional stent. Malapposition exposes patients to serious risk of recurrence of the heart attack. The study confirmed the value of STENTYS breakthrough technology.

Launch of the Apposition III clinical trial

In December 2010, STENTYS announced the launch of the Apposition III international clinical trial of its self-apposing stent. The results of this trial, which will enroll 500 patients, will confirm the medical value of STENTYS self-apposing stent in treating heart attacks and will support an acceleration of its penetration in Europe.

- Corporate governance

Appointment of Michel Darnaud

Michel Darnaud joined the STENTYS Board of Directors in November 2010. A seasoned medical technology industry professional, Michel Darnaud has been President of Sorin group's cardiopulmonary and intercontinental division since 2008.

- Finance

Success of the IPO

STENTYS successful IPO resulted in a capital increase of €22.7 million. STENTYS has been listed on NYSE Euronext Paris since 25 October 2010.

- **Perspectives for 2011**

Gonzague Issenmann, CEO and co-founder of STENTYS concludes: *"The Company has developed and obtained European authorisation for its revolutionary product in less than 4 years. It now enters a "controlled release" phase that aims to establish STENTYS' self-apposing technology as the standard of care in acute myocardial infarction. We are very confident on the progress of our clinical program and on the growth of revenues, and will continue to apply stringent controls to our cost structure."*

- **Calendar of Future Publications**

STENTYS' revenues for the first quarter of 2011 will be released on May 11 2011.

About Stentys

Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries.

More information on www.stentys.com

Contacts:
Stentys
Stanislas Piot
CFO
Tel.: +33 (0)1 44 53 99 42
stan.p@stentys.com

NewCap.
Investor relations & Financial Communications
Axelle Vuillermet / Pierre Laurent
Tel.: +33 (0)1 44 71 94 94
stentys@newcap.fr

STENTYS is listed on NYSE Euronext Paris
ISIN: FR0010949404 – STNT